As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

MBA Strategic Thinking For Pharma And Biopharma Professionals Training Course - Register Now For The Two Day Online Event On February 24-25, 2025 ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

AIM ImmunoTech (AIM) announced that the final Clinical Study Results for the “Study to Evaluate the Efficacy and Safety of Ampligen in Patients ...

Oversubscribed Seed Round Accelerates Nasdepi®'s Journey as the First Dry Powder Nasal, Heat-Stable Treatment for Anaphylaxis RALEIGH, NORTH CAROLINA / ACCESS Newswire / January 21, 2025 / Belhaven ...

Kiromic BioPharma (KRBP) reports favorable efficacy results from the 12-month follow-up visit for the first patient and the two-month follow-up ...

Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports favorable efficacy results from the 12-month ...

The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 ...